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A B S T R A C T
Background: Despite encouraging declines in the incidence of heart failure (HF) complicating acute
coronary syndrome (ACS), it remains a common problem with high mortality. Being able to identify
patients at high risk of HF after ACS would have great clinical and economic impact. With this study, we
assessed the usefulness of the GRACE score to predict HF after an ACS.
Methods: We studied 4137 consecutive patients discharged with diagnosis of ACS. We analyzed HF
incidence, timing, and association with the follow-up mortality. Cox proportional hazards modeling was
performed to assess the accuracy of the GRACE risk score to predict HF admissions in follow-up (median
3.1 years).
Results: A total of 433 patients (10.5%) developed HF. GRACE score was an independent predictor of HF
after ACS [hazard ratio (HR) 1.02, 95% conﬁdence interval (CI): 1.01–1.03, p < 0.001]. A risk gradient for
the development of HF with GRACE risk score was shown: high- and moderate-GRACE risk groups have
been linked to a sixfold and twofold increased risk of HF. This risk gradient was maintained in patients
with and without prior history of HF, in ST elevation myocardial infarction and non-ST elevation
myocardial infarction groups, and in patients with depressed and preserved left ventricular ejection
fraction. The development of HF was associated with high mortality (54.5% vs 13.4%; HR = 4.48; 95% CI:
3.84–5.24; p < 0.001). After adjusting for GRACE risk score, HF development resulted as an independent
predictor of mortality.
Conclusion: GRACE risk score has been shown to provide clinically relevant stratiﬁcation of follow-up HF
admission risk at the time of hospital discharge in patients with ACS.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Heart failure (HF) is a prevalent and morbid chronic illness
[1]. According to the European Society of Cardiology (ESC) and the
American College of Cardiology (ACC)/American Heart Association
(AHA), HF affects approximately 15 million Europeans and over
5 million Americans [2,3].* Corresponding author at: Cardiology Department, Clinical University Hospital
of Santiago de Compostela, Travesı´a Choupana s/n, 15706 Santiago de Compostela,
A Corun˜a, Spain. Tel.: +34 981 950 000; fax: +34 981 950 750.
E-mail address: raposeiras26@hotmail.com (S. Raposeiras-Roubı´n).
http://dx.doi.org/10.1016/j.jjcc.2014.12.015
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsIschemic heart disease is a leading cause of HF, which often
develops as a complication of acute coronary syndrome (ACS)
[4]. The treatment of ACS has improved dramatically in recent
decades with the advent of early reperfusion strategies, including
percutaneous coronary intervention (PCI) and evidence-based
pharmacotherapies [5]. However, although the follow-up and in-
hospital case-fatality rates of ACS have fallen dramatically over
recent decades, HF complicating ACS in the short and long terms
continues to be associated with high mortality [6]. Identifying
predictors of HF among ACS patients will help physicians to
improve risk stratiﬁcation and to determine the optimal post-
discharge plan for preventing readmission [7]. Many predictors of
HF admission have been recognized and can be organized into reserved.
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and psychosocial factors [1]. These factors interact with each
other; accordingly it is necessary to integrate them in a simple
model of easy application in the daily clinical practice [8].
Given the poor prognosis posed by HF after ACS, we consider it
relevant to stratify the patients according to this risk. With the
present study, we aim to analyze the utility and predictive value of
GRACE risk score [9] to predict the development of HF in a
contemporary cohort of ACS patients after discharge.
Methods
Study design
The CardioCHUS registry is a database of all ACS patients who
were consecutively admitted to the Cardiology Department of our
center from December 2003 through February 2011 (n = 4503).
Diagnosis of ACS was therefore validated if the patient had new
onset symptoms consistent with cardiac ischemia and at least one
of the following: cardiac biomarkers above the higher normal
laboratory limit, electrocardiogram changes consistent with ACS,
in-hospital stress testing showing ischemia, or documented
history of coronary vessel disease. Patients were classiﬁed as
having ST elevation myocardial infarction (STEMI) or non-ST
elevation ACS (NSTE-ACS, that includes unstable angina and non-
ST elevation myocardial infarction, NSTEMI). The diagnosis of
unstable angina required the presence of suggestive symptoms
together with objective evidence of myocardial ischemia on stress
testing or detection of a culprit lesion of 50% on coronary
angiography, in addition to cardiac biomarkers below the higher
normal laboratory limit.
Starting from the original registry, we selected those patients
who survived the hospital phase and were discharged (n = 4229).
Demographic, clinical and angiographic data, as well as
information relating to management and in-hospital complica-
tions, were collected prospectively and recorded in a computer
database by the department’s cardiologists in the hospitalization
ward and coronary care unit. Follow-up data were obtained in
97.8% of the patients (a total of 92 cases were missed; ﬁnal
cohort = 4137 patients).
Calculating the GRACE score
The GRACE risk score at discharge was calculated for each
patient by assigning the appropriate number of points for each of
the 9 prognostic variables that enter into the calculation [9]: age,
history of heart failure, history of acute myocardial infarction
(AMI), heart rate and systolic blood pressure at admission, ST
segment depression, serum creatinine at admission, elevated
myocardial necrosis markers or enzymes, and lack of percutaneous
coronary revascularization during admission.
Three risk categories were established using the cut-off points
set out in the GRACE study. Therefore, in the low-risk category, the
GRACE score was 27–99 points for STEMI and 1–88 for NSTE-ACS;
in the intermediate-risk category, the score for STEMI was 100–
127, and 89–118 for NSTE-ACS; and in the high-risk category, the
score for STEMI was 128–263 and 119–263 for NSTE-ACS.
Endpoints and follow-up
The primary endpoint considered in this study was deﬁned as
the ﬁrst hospitalization due to HF after ACS discharge. The
diagnosis of HF was established based on clinical criteria and a
structural and/or functional heart anomaly was detectable by
echocardiography, according to the diagnostic criteria for HF
proposed by the ESC. Secondary, follow-up mortality was alsodetermined for the whole patient population and was then
compared between those who did and did not experience a HF
admission after ACS discharge, and also in each GRACE risk group.
Statistical analysis
To analyze the predictors for the endpoint, data from the
clinical history were taken as independent variables. Continuous
variables were expressed as the mean  standard deviation (SD)
and compared by the unpaired t-test. Categorical variables were
expressed as percentages and compared by the chi-square test.
Univariate variables that were associated with the study endpoint
were identiﬁed. To assess prognostic value of GRACE risk score to
predict HF admission during follow-up, a model was generated using
stepwise logistic multivariate analysis by Cox regression, which
included those variables that were signiﬁcantly (p < 0.10) associated
with any of the study endpoints on univariate analysis. The hazard
ratios (HRs) and their 95% conﬁdence intervals (CIs) were calculated.
The predictive performance of the model was assessed with c-
statistics. Cumulative survival curves for the occurrence of the study
endpoint were performed by the Kaplan–Meier method and
compared by the log-rank test. Calculations were performed using
the SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA). Statistical
signiﬁcance was considered for p < 0.05.
Results
Baseline characteristics
The mean age of the patients was 66.9  12.8 years and 1165
(28.2%) were women. There was a prior history of hypertension in
2358 (57.0%), diabetes in 1095 (26.5%), myocardial infarction in 503
(12.2%), and HF in 169 (4.1%). STEMI was present in 1304 (31.6%),
non-STEMI in 2124 patients (51.3%), and unstable angina in 709
(17.1%); 2662 patients (64.3%) underwent PCI.
The proportion of patients in each of the 3 risk categories
according to GRACE risk score is shown in Table 1. The high-risk
category contained 1573 (38.0%) of the patients.
Heart failure in follow-up
Of the 4137 patients included, 433 (10.5%) developed HF during
the follow-up (median 3.1 years, interquartile range 1.4–4.9). The
median time for the appearance of this complication was
10 months (3–27). The incidence of events was distributed
asymmetrically over time. In the ﬁrst year the incidence of HF
was 5.6%, after which it was close to 2% per year. In 225 from those
433 patients there was history of prior HF (52.0%); 208 presented
de novo HF during follow-up (5.0% from the total population).
Among those who developed HF, 103 (23.8%) suffered a recurrence
of AMI before this complication arose.
Table 2 shows the main characteristics of the patients who
developed and who did not develop HF. Those who developed HF in
follow-up were older, with lower estimated glomerular ﬁltration
rate and a lower left ventricular ejection fraction (LVEF). The
cardiovascular risk factors were also distributed asymmetrically:
diabetes, hypertension, dyslipidemia, peripheral vascular disease,
prior MI, prior HF, and prior stroke.
Utility of GRACE risk score
We have shown a risk gradient for the development of HF with
GRACE risk score (Fig. 1). This risk gradient was maintained in
patients with and without prior history of HF (Fig. 1A), in STEMI
Table 1
Baseline characteristics, in-hospital complications, and management of CardioCHUS population according to GRACE risk groups.
Variables Low risk (n = 1208; 29.2%) Moderate risk (n = 1356; 32.8%) High risk (n = 1573; 38.0%) p-Value
Age, years 52.7  8.4 67.2  7.9 77.6  7.5 <0.001
Female sex, % 16.8 28.2 36.9 <0.001
Diabetes, % 15.7 27.9 33.5 <0.001
Hypertension, % 40.0 58.3 69.0 <0.001
Dyslipidemia, % 45.2 49.1 41.6 <0.001
Peripheral artery disease, % 4.3 8.6 13.5 <0.001
Prior myocardial infarction, % 4.4 10.3 19.7 <0.001
Prior heart failure, % 0.6 1.7 8.8 <0.001
Prior stroke, % 2.2 5.2 10.7 <0.001
COPD, % 4.1 8.6 17.2 <0.001
Atrial ﬁbrillation, % 1.4 6.9 20.8 <0.001
STEMI, % 37.0 29.2 29.3 <0.001
Killip  II, % 0.6 3.8 36.9 <0.001
Main left coronary artery, % 1.7 3.1 6.2 <0.001
Proximal LAD, % 12.3 12.5 13.7 0.515
Multivessel coronary disease, % 31.5 40.9 38.6 <0.001
Left ventricular ejection fraction, % 58.6  8.2 57.4  9.9 52.4  12.5 <0.001
Troponin I peak, ng/mL 27.0  56.1 26.5  63.3 33.3  187.7 0.261
Hemoglobin, g/dL 13.9  3.9 13.1  1.6 12.1  1.7 <0.001
MDRD-4, mL/min/1.73 m2 89.5  56.4 76.4  26.1 62.0  27.3 <0.001
PCI, % 79.3 70.5 47.6 <0.001
CABG, % 2.8 4.3 6.1 <0.001
Complete revascularization, % 59.2 45.6 28.7 <0.001
Amines, % 0.4 1.3 5.1 <0.001
Intra-aortic balloon pump, % 0.4 0.4 1.4 0.003
In-hospital re-infarction, % 2.5 1.3 2.1 0.065
In-hospital heart failure, % 1.0 1.5 8.1 <0.001
Dual antiplatelet therapy, % 81.0 74.9 60.5 <0.001
Beta-blockers, % 78.4 71.4 56.6 <0.001
ACEI/ARB, % 58.8 61.9 60.3 0.277
Statins, % 88.5 85.8 77.2 <0.001
Spironolactone, % 1.6 3.7 8.3 <0.001
Digoxin, % 0.2 1.3 5.3 <0.001
ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CABG, coronary artery by-pass graft surgery; COPD, chronic obstructive pulmonary
disease; LAD, left anterior descending artery; MDRD-4, Modiﬁcation of Diet in Renal Disease-4 variable calculation for glomerular ﬁltration rate; PCI, percutaneous
coronary intervention; STEMI, ST-segment elevation myocardial infarction.
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preserved LVEF (Fig. 1C). As a continuous variable, the HR of GRACE
risk score to predict follow-up HF was 1.03 (95% CI: 1.02–1.04,
p < 0.001).
Independent predictors of HF
Multivariate analysis identiﬁed 10 independent predictors
(Fig. 2) that allow the risk of developing HF to be predicted:
diabetes mellitus, hypertension, peripheral artery disease, prior
HF, chronic obstructive pulmonary disease, atrial ﬁbrillation, NST-
ACS, anemia, depressed LVEF, and GRACE risk score. The c-statistic
of the model was 0.82  0.01. After adjusting by hospitalized year,
the results have not been altered (in supplementary table we
provided information about the changes in the treatment at discharge
during the registration period).
Supplementary table related to this article can be found, in the
online version, at doi:10.1016/j.jjcc.2014.12.015.
Fig. 3 shows the independent value of GRACE score to stratify
the risk of HF after ACS (HR 1.02, 95% CI: 1.01–1.03, p < 0.001).
Implications of post-ACS heart failure
The development of HF was associated with high mortality
(54.5% vs 13.4%; HR = 4.48; 95% CI: 3.84–5.24; p < 0.001). Fig. 4
shows the difference in mortality over time for these 2 groups
(development or not of HF after ACS discharge) and for the
different GRACE risk subgroups. After adjusting for GRACE risk
score, HF development resulted an independent predictor of
mortality (HR 2.29, 95% CI: 1.72–2.40, p < 0.001).Discussion
The present study has evaluated the ability of GRACE risk score
to predict HF admission after ACS discharge. We have shown that
GRACE risk score at the time of hospital discharge provides a good
estimation of an individual patient’s risk of an adverse outcome.
With this risk score, contemporary patients with ACS can be
allocated to low-, intermediate-, or high-risk categories for the
occurrence of not only cardiovascular mortality but also of HF
during short- and long-term follow-up.
The utility of the GRACE risk score to establish the risk of HF
after ACS has great clinical and economic implications [9–11]. After
an ACS, the patient is in a risk stage of developing HF (stage B of the
AHA) [3]. Ischemic heart disease is the leading cause of HF with
depressed LVEF in developed countries. However, only 1 of
10 patients with ACS develops HF during follow-up [12]. Therefore,
risk stratiﬁcation of these patients to predict HF is useful to focus
the outpatient coronary care. Our results emphasize the impor-
tance of optimizing medical therapy, especially with beta-blockers
and angiotensin-converting enzyme inhibitors, in patients at high-
risk GRACE, for their potential risk for developing HF. Perhaps a
generalization of these therapies in patients at high risk of HF,
including also spironolactone or eplerenone, may help to prevent
adverse ventricular remodeling [13] and to prevent the develop-
ment of HF.
Despite myriad established clinical predictors, it is difﬁcult to
assemble a risk model for follow-up HF admission that is robust
and actionable [14]. Many correlate strongly with echocardio-
graphic ﬁlling patterns, some with the levels of cardiac biomarkers
including natriuretic peptides [15] and cardiac troponins [16], and
others with indicators of neurohormonal activation, including
Table 2
Baseline characteristics of the study population stratiﬁed by groups according to whether or not they developed heart failure during the follow-up period.
Variables Heart failure admission (N = 433) Free of heart failure admission (N = 3704) p-Value
Age, years 74.7  9.6 66.0  12.9 <0.001
Female sex, % 31.4 27.8 0.112
Diabetes, % 50.6 23.7 <0.001
Hypertension, % 75.1 54.9 <0.001
Dyslipidemia, % 50.8 44.4 0.012
Peripheral artery disease, % 19.6 8.0 <0.001
Prior myocardial infarction, % 22.6 10.9 <0.001
Prior heart failure, % 17.3 2.5 <0.001
Prior stroke, % 12.9 5.6 <0.001
COPD, % 24.9 8.9 <0.001
Atrial ﬁbrillation, % 25.2 8.9 <0.001
STEMI, % 24.7 32.3 0.001
Killip  II, % 42.7 12.3 <0.001
Main left coronary artery, % 6.9 3.5 0.001
Proximal LAD, % 15.2 12.6 0.126
Multivessel coronary disease, % 42.5 36.7 0.018
LVEF, % 49.7  13.7 56.5  10.3 <0.001
Troponin I peak, ng/mL 29.7  77.0 29.2  129.4 0.906
Hemoglobin, g/dL 11.9  1.9 13.1  2.7 <0.001
MDRD-4, mL/min/1.73 m2 61.5  28.7 76.3  40.3 <0.001
PCI, % 50.1 66.0 <0.001
CABG, % 5.5 4.4 0.292
Complete revascularization, % 28.6 44.8 <0.001
Amines, % 6.2 2.0 <0.001
Intra-aortic balloon pump, % 1.6 0.7 0.043
In-hospital re-infarction, % 1.2 2.0 0.213
In-hospital heart failure, % 11.1 3.1 <0.001
Dual antiplatelet therapy, % 63.0 72.2 <0.001
Beta-blockers, % 53.8 69.5 <0.001
ACEI/ARB, % 62.4 60.2 0.375
Statins, % 78.3 83.9 0.003
Spironolactone, % 13.4 3.8 <0.001
Digoxin, % 8.1 1.9 <0.001
6-Month GRACE, points 140.5  30.3 109.7  32.2 <0.001
ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CABG, coronary artery by-pass graft surgery; COPD, chronic obstructive pulmonary
disease; LAD, left anterior descending artery; MDRD-4, Modiﬁcation of Diet in Renal Disease-4 variable calculation for glomerular ﬁltration rate; PCI, percutaneous
coronary intervention; STEMI, ST-segment elevation myocardial infarction.
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system metabolites or lower levels of serum sodium [17]. Associ-
ated diagnoses, including, atrial ﬁbrillation, multivessel coronary
disease, and hypertension, confer higher risk for cardiovascular
admission [18], whereas the burden of comorbid noncardiac
illness, including chronic renal disease [19], diabetes mellitus,
anemia, and pulmonary disease, raises the risk for both HF and
non-HF-related complications [20]. So, although there are numer-
ous established prognostic markers, they usually coexist and their
importance hinges on the inter-relationship of many factors.
Because patients often present with complex risk proﬁles,
assimilation of all the relevant information from history, physical
examination, and laboratory investigations is a highly complicated
process and a daunting task for a busy clinician. ACC/AHA and ESC
guidelines state that estimation of the level of risk is a
multivariable problem that cannot be accurately quantiﬁed with
a simple table, highlighting the importance of using risk scores
[2,3]. Despite the proven utility of risk scores in prognostication
and guidance of treatment strategies, it is not known how often
they are actually used in routine practice [21]. Physicians may be
reluctant to use risk scores at the bedside because they ﬁnd it
inconvenient and time consuming. Others believe that they can
readily discern and integrate high-risk features into overall risk
estimation without the aid of risk scores. To date, no risk score has
been proven to predict HF after ACS.
Risk scores are simple prognostication schemes that categorize
a patient’s risk of death and cardiovascular events [22]. Their use
can help tailor our therapies to match the intensity of the patient’s
ACS. The ideal score for risk stratiﬁcation for ACS patients should
have a good balance between complexity and utility [23]. GRACErisk score has shown its utility in the setting of ACS, to predict in-
hospital and follow-up mortality and reinfarction [24,25]. Using
the GRACE risk score, one could calculate even more precisely the
risk and the associated mortality rate compared with other risk
scores [23]. As GRACE risk score includes continuous variables such
as age, heart rate, and serum creatinine, it needs digital assistant
applications to calculate, that signiﬁcantly simplify these complex
calculations such that, at the present time, the complexity of a
score is essentially determined by factors related to data collection,
rather than the methodology involved in the calculations
[9]. Hence, using GRACE risk score in the daily risk assessment
of ACS patients can only help us. Our group had previously
validated the GRACE score for predicting death after ACS
[10]. However, the usefulness of GRACE risk score to predict HF
after ACS had never been validated scientiﬁcally so far. To the best
of our knowledge, this is the ﬁrst time that this was analyzed.
GRACE risk score has resulted as a good tool to predict follow-up
HF in the total ACS population and in the different subgroups,
according to type of ACS (STEMI and NSTE-ACS) and LVEF
(preserved and depressed). And it maintained its prognostic value
also to predict de novo HF, being independent of revascularization.
It should be noted that based on obtained HRs the risk of HF after
an ACS is twofold higher in patients with moderate-GRACE risk and
sixfold higher in patients at high risk, compared to low-risk
patients according to GRACE risk score.
Elucidation of speciﬁc risk models for HF admission may be
most useful when it helps to reveal new physiological targets or
characteristic patient proﬁles for focused intervention, either
medical or social [14]. The most effective application of risk
stratiﬁcation may be to help guide the management of outpatient
Fig. 1. Risk gradient for the development of HF during the follow-up after ACS discharge according to GRACE risk score in different subgroups. HF, heart failure; ACS, acute
coronary syndrome; STEMI, ST-elevation myocardial infarction; NST, non-ST elevation; LVEF, left ventricular ejection fraction.
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Fig. 2. Independent predictors of heart failure after acute coronary syndrome discharge. HF, heart failure; COPD, chronic obstructive pulmonary disease; NSTE-ACS, non-ST
elevation acute coronary syndrome; LVEF, left ventricular ejection fraction.
Fig. 3. Cumulative survival curve for the occurrence of heart failure (HF) after acute
coronary syndrome discharge according to GRACE risk score after adjusting by the
other independent predictors of the endpoint.
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follow-up. However, it should be emphasized that risk scores are
clinical tools that can supplement but not replace sound clinical
judgment. An increasing body of literature attempts to describe
and validate hospital HF admission risk prediction tools [26]. In-
terest in such models has grown for two reasons. First, transitional
care interventions may reduce HF admissions. HF admission risk
assessment could be used to help target the delivery of these
resource-intensive interventions to the patients at greatest risk
after ACS [26]. Second, there is interest in using readmission rates
as a quality metric. The US Centers for Medicare & Medicaid
Services (CMS) recently began using readmission rates as a
publicly reported metric and has plans to lower reimbursement
to hospitals with excess risk-standardized readmission rates
[27]. The use of GRACE risk score brings some reﬁnement to the
prediction of readmission risk, as it differentiates those with low
risk from those at intermediate and high risk (a much more precise
process than assuming that all previously hospitalized patients
have equally high risk). From the health services research
viewpoint, our ﬁndings may be of use in comparing risk-stratiﬁed
HF admission rates among groups of patients.
Clinical implications
The potential implications of our study deserve comment. From
the clinical viewpoint, quantiﬁcation of HF admission risk at the
time of hospital discharge is of value in that it provides the
opportunity to enroll high-risk patients into proactive care
management programs, in order to reduce costs from hospitaliza-
tion for HF while improving quality of care and patient functional
status. GRACE risk score has been shown to provide clinically
relevant stratiﬁcation of follow-up HF admission risk. With good
predictive ability and using reliable data that can be easily
obtained, the GRACE model gives information early enough during
the hospitalization – prior to discharge – to trigger a transitionalcare intervention, many of which involve discharge planning and
begin well before hospital discharge.
Limitations
These data must be interpreted in the context of this study’s
limitations. First, it is a retrospective analysis of clinical unicenter
data. Although we have used a multivariable model to adjust for
potential confounders, there may remain unmeasured or residual
confounding. Second, we have no data regarding medication
compliance and socioeconomic and educational variables, which
can affect the occurrence of HF in follow-up. Third, we do not have
data about any biomarker with utility in HF, such as B-type
natriuretic peptide, mid-regional pro-atrial natriuretic peptide,
Fig. 4. Kaplan–Meier survival curves stratiﬁed by follow-up heart failure (HF)
development and GRACE risk groups.
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Therefore, we cannot compare the predictive value of GRACE risk
score with these validated biomarkers.
Conclusions
The calculation of GRACE risk score at the time of hospital
discharge after an ACS facilitates the identiﬁcation of individual
patients who are at high risk of developing HF in follow-up, being a
critical step in the goal to reduce mortality and cardiovascular
hospital readmission rates. This could lead to design future
interventions that have the potential to limit HF admissions, reduce
healthcare costs, and improve care in this vulnerable population.
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